|
Volumn 21, Issue 17, 2013, Pages 5246-5260
|
Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors
|
Author keywords
Anti tumor; c Met; Kinase inhibitor; Quinoline; Semicarbazone
|
Indexed keywords
FORETINIB;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (4 METHYLPIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (2 FLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (4 METHYLPIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (2,4 DIFLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (4 METHYLPIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 CHLOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (4 METHYLPIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 FLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (4 METHYLPIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (BENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (2 CYANOBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (2 FLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (2 NITROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (2 TRIFLUOROMETHYLBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (2,4 DIFLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (2,5 DIMETHOXYBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (3 METHOXYBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (3 NITROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (3,4 DIFLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 CHLOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 FLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 NITROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PIPERIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (BENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 CHLOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 FLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (BENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 MORPHOLINO PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 CHLOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 MORPHOLINO PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 FLUOROBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 MORPHOLINO PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 TRIFLUOROMETHOXYBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 MORPHOLINO PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (4 TRIFLUOROMETHYLBENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6 METHOXY 7 (3 MORPHOLINO PROPOXY)QUINOLIN 4 YLOXY)PHENYL] N4 (BENZYLIDENE)SEMICARBAZIDE;
N1 [3 FLUORO 4 (6,7 DISUBSTITUTED QUINOLIN 4 YLOXY)PHENYL] N4 ARYLIDENESEMICARBAZIDE DERIVATIVE;
PROTEIN TYROSINE KINASE INHIBITOR;
UNCLASSIFIED DRUG;
ANTIPROLIFERATIVE ACTIVITY;
ARTICLE;
BREAST CANCER;
CANCER CELL;
CANCER CELL CULTURE;
COLORECTAL CANCER;
CONTROLLED STUDY;
CYTOTOXICITY;
DRUG POTENCY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
ENZYME INHIBITION;
HETERONUCLEAR NUCLEAR MAGNETIC RESONANCE;
HUMAN;
HUMAN CELL;
IC 50;
IN VITRO STUDY;
LUNG NON SMALL CELL CANCER;
NUCLEAR OVERHAUSER EFFECT;
PROTEIN PHOSPHORYLATION;
STOMACH CANCER;
STRUCTURE ACTIVITY RELATION;
ANTI-TUMOR;
C-MET;
KINASE INHIBITOR;
QUINOLINE;
SEMICARBAZONE;
ANTINEOPLASTIC AGENTS;
BINDING SITES;
CELL LINE, TUMOR;
CELL SURVIVAL;
DRUG EVALUATION, PRECLINICAL;
DRUG SCREENING ASSAYS, ANTITUMOR;
HT29 CELLS;
HUMANS;
MOLECULAR DOCKING SIMULATION;
PHOSPHORYLATION;
PROTEIN BINDING;
PROTEIN KINASE INHIBITORS;
PROTEIN STRUCTURE, TERTIARY;
PROTO-ONCOGENE PROTEINS C-MET;
QUINOLINES;
SEMICARBAZIDES;
SEMICARBAZONES;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 84881372377
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2013.06.026 Document Type: Article |
Times cited : (48)
|
References (33)
|